BNP Paribas Asset Management
CRNX icon

BNP Paribas Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

BNP Paribas Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.8M Sell
1,678,490
-37,955
-2% -$1.41M 0.06% 289
2026
Q1 		$62.3M Buy
1,716,445
+389,063
+29% +$17.4M 0.07% 265
2025
Q4 		$61.8M Buy
1,327,382
+493,351
+59% +$22M 0.07% 254
2025
Q3 		$34.7M Buy
834,031
+121,312
+17% +$3.88M 0.09% 234
2025
Q2 		$20.5M Buy
712,719
+101,880
+17% +$3.15M 0.05% 347
2025
Q1 		$20.5M Buy
610,839
+34,771
+6% +$1.3M 0.05% 336
2024
Q4 		$29.5M Buy
576,068
+84,687
+17% +$4.74M 0.07% 263
2024
Q3 		$25.1M Sell
491,381
-54,853
-10% -$2.83M 0.06% 271
2024
Q2 		$24.5M Buy
546,234
+3,526
+0.6% +$163K 0.06% 267
2024
Q1 		$25.4M Sell
542,708
-115,581
-18% -$4.52M 0.07% 272
2023
Q4 		$23.4M Buy
658,289
+24,925
+4% +$764K 0.07% 280
2023
Q3 		$18.8M Sell
633,364
-7,981
-1% -$164K 0.06% 301
2023
Q2 		$11.6M Sell
641,345
-49,856
-7% -$994K 0.04% 380
2023
Q1 		$11.1M Buy
691,201
+80,511
+13% +$1.49M 0.04% 406
2022
Q4 		$11.2M Buy
610,690
+155,271
+34% +$2.74M 0.04% 401
2022
Q3 		$8.94M Buy
+455,419
New +$9.29M 0.04% 430

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Asset Management's CRNX Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 2.2% in Q2 2026, selling an estimated $1.41M and leaving 1,678,490 shares worth $62.8M. The position accounts for 0.06% of the portfolio, ranked #289.

BNP Paribas Asset Management first reported a position in CRNX in Q3 2022 and has held it in 16 quarters since. 185 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • BNP Paribas Asset Management held 1,678,490 shares of Crinetics Pharmaceuticals worth $62.8M as of Q2 2026.
  • BNP Paribas Asset Management sold 37,955 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.41M.
  • Crinetics Pharmaceuticals made up 0.06% of BNP Paribas Asset Management's portfolio in Q2 2026, its #289 holding.
  • BNP Paribas Asset Management first reported a position in Crinetics Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • 185 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.